The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL

Emily Curran, MD, The University of Cincinnati, Cincinnati, OH, comments on how inotuzumab ozogamicin is currently used in the treatment of acute lymphoblastic leukemia (ALL) and how that may change in the future. Whilst the role of inotuzumab ozogamicin in pediatric patients remains unclear, Dr Curran argues that this drug may play an important role in the treatment of older patients who cannot tolerate intensive chemotherapy This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Be the first to comment